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Vortioxetine is a multimodal antidepressant working through 
several serotonergic targets. It is a 5-HT3, 5-HT7 and 5-HT1D 
receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A 
receptor agonist and inhibitor of the 5-HT transporter (SERT) in 
vitro, displaying highest affinities for SERT and 5-HT3 (Bang-
Andersen et al., 2011) . In vivo, this profile leads to increases in 
acetylcholine, dopamine and noradrenaline levels in both the 
frontal cortex and ventral hippocampus (Mørk et al., 2012). 
Vortioxetine is active in a number of preclinical behavioural 
models predictive of antidepressant and anxiolytic activity and is 
an efficacious antidepressant in clinical studies (Berhan and 
Barker, 2014; Fu and Chen, 2015; Guilloux et al., 2013). Since 
vortioxetine has a novel pharmacological profile in animal mod-
els it would be of benefit to be able to demonstrate this in humans. 
This study set out to evaluate, using sleep architecture in healthy 
humans, the brain effects of vortioxetine, compared with a potent 
serotonin reuptake inhibitor (SRI), paroxetine, for which a con-
siderable amount of sleep data were available. At the same time 
the plasma concentration of the two drugs was measured and 
related to the SERT occupancy estimated from previous PET 
studies (Areberg et al., 2012a; Meyer et al., 2004) so that the 
observed effects on sleep could be related to plasma levels and 
SERT occupancy.
The structure of human sleep is well described and is a sensi-
tive measure of drug effects in the brain, particularly those of 
antidepressants, where it is possible to identify differences 
between compounds with different pharmacologic profiles 
(Paterson et al., 2011). In particular SRIs exhibit acute and easily 
detectable changes in REM sleep; these effects are dose-related 
in both patients and healthy subjects and consist of a reduction in 
the overall amount of REM sleep during the night, and a delay in 
the first entry into REM sleep (increased REM onset latency 
(ROL)) (Wilson and Argyropoulos, 2005). REM sleep suppres-
sion after SRI administration is likely to result from increased 
levels of synaptic 5-HT and may be mediated through the 5-HT1A 
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receptor. This observation is based on both preclinical and human 
studies; Monaca et al. (2003) showed that the REM sleep sup-
pressing effect of citalopram was absent in 5-HT1A knockout 
mice, while in humans selective 5-HT1A receptor agonist drugs 
are strongly REM sleep suppressing (Driver et al., 1995; Wilson 
et al., 2005).
The effects of the other receptor interactions of vortioxetine 
are less well understood. 5-HT3 antagonists have been shown to 
shorten REM latency whereas 5-HT3 agonists may lengthen it, 
both in rodents and in humans (Adrien et al., 1992; Monti and 
Jantos, 2008; Rothe et al., 1994; Staner et al., 2001). A 5-HT7 
antagonist suppressed REM sleep and increased ROL in both 
rodents and humans (Bonaventure et al., 2012).
Changes in sleep initiation and sleep continuity after short-
term administration of SSRIs are also similar in healthy subjects 
and depressed patients, consisting of increased light (stage 1) 
sleep, an increased number of arousals from sleep, and an 
increased time spent awake at night. Collectively these changes 
in sleep continuity are described as sleep fragmentation. 
Fragmentation of sleep is probably not explained by stimulation 
of the 5-HT1A receptors responsible for REM sleep effects, as 
potent 5-HT1A receptor agonists do not have such marked sleep-
fragmenting effects.
It was expected that the pharmacologic profile of vortioxetine 
as an SRI and an antagonist at various 5-HT receptors would 
mean that its effect on sleep would differ from those of a pure 
reuptake inhibitor. We measured sleep after three days’ dosing 
with 20 or 40mg/day of vortioxetine, to approximate the steady 
state conditions reached clinically with 10 and 20mg, respec-
tively, and compared this with three days’ dosing of paroxetine, 
for which we had data from a previous study (Wilson et al., 
2004). There were no sleep data for vortioxetine in humans avail-
able at the time of the study, so we estimated that 24 participants 
would be appropriate based on REM and sleep fragmentation 
results from this study of two SRIs.
Method
This was a randomised, double-blind, four-way crossover, pla-
cebo controlled, active comparator polysomnographic study in 
healthy young men. The study was conducted at Hammersmith 
Medicines Research, London, United Kingdom, and regulatory 
approval was obtained from the National Research Ethics Service 
(Edinburgh Independent Ethics Committee for Medical Research) 
and the EudraCT National Competent Body (MHRA). It was 
conducted according to good clinical practice guidelines (The 
Medicines for Human Use (Clinical Trials) Regulations, 2004).
Study design
Twenty-four healthy subjects were recruited. The eligibility of 
the subjects was initially assessed at a screening visit (day -21 
to day -3). They were randomly allocated to one of 24 treatment 
sequences (1 subject per treatment sequence). Each treatment 
sequence consisted of administration of vortioxetine 20mg, 
vortioxetine 40mg, paroxetine 20mg or placebo for three con-
secutive days, and each treatment was separated by a washout 
period of three weeks. Actigraphy was recorded during a mini-
mum of five consecutive days leading up to day -2 and for the 
entire duration of the washout periods for the purpose of exclud-
ing subjects with irregular sleep-wake rhythms. Eligible sub-
jects were admitted to the research centre on day -2, and were 
dosed at 09:00 on days 1, 2 and 3 of each treatment period (peri-
ods 1–4). Sleep recordings (polysomnography, PSG) were per-
formed in each treatment period on day -2 (familiarisation with 
procedure), day -1(baseline) and day 3. At predetermined time 
points, blood samples were drawn for drug concentration analy-
sis of vortioxetine and paroxetine. Safety and tolerability were 
assessed throughout the study.
Participants
Participants were healthy, drug-free young men between the ages 
of 20 and 34 years with a BMI between 20 and 29 kg/m2. They 
were required to have a regular sleep pattern with habitual bed-
time between 22:00 and 00:00 and a rising time between 06:00 
and 08:00. This was checked when actigraphs were downloaded 
upon admission at each visit, and the visit was postponed if they 
had been non-compliant in the previous five days. Alcohol breath 
test and drugs of abuse urine tests were conducted at each visit. A 
blood sample for genotyping for polymorphisms in cytochrome 
P450 (CYP 2D6, 2C9, 2C19) was obtained at screening. CYP 
2D6 is the main isozyme involved in the metabolism of paroxe-
tine and vortioxetine, although the other two are also important 
for the latter.
Polysomnography (PSG)
For each night with PSG assessments, (days -2, -1, 3) subjects 
were set up for measurements of PSG sleep parameters according 
to standard methods, using an Embla PSG system with N7000 
amplifiers. Silver-silver chloride electrodes were placed accord-
ing to the International 10–20 system and the recommendations 
of Rechtschaffen and Kales (1968) to ensure standardisation, 
comparability, and replicability of EEG signals, and included 
electrooculogram and electromyograms from chin and leg (ante-
rior tibialis) muscles. In addition, on day -2 in period 1, respira-
tion was monitored using respiratory bands and a thermistor, 
arterial oxygen saturation was measured using a pulse oximeter, 
and the subject was recorded on video overnight. This was to 
exclude the possibility of a sleep disorder and video recordings 
were deleted after subject eligibility had been verified.
Subjects went to bed and got up at their usual time as noted at 
screening and were required to maintain this routine throughout 
the study. Recordings commenced after calibration and contin-
ued throughout the night for eight hours or until the subject woke 
up (whichever was first). The data were analysed and scored 
according to Rechtschaffen and Kales’ (1968) criteria by an 
experienced sleep scorer blind to treatment condition. Measures 
derived from the PSG data included: staging time (time between 
eyes closed at bedtime and eyes open at rising time), sleep onset 
latency (from beginning of staging time to beginning of the first 
continuous 2-minute period not classified as awake or stage 1 
sleep), total sleep time (TST), sleep efficiency, wake after sleep 
onset (WASO), number of awakenings (of at least 15 seconds in 
length), number of shifts to stage 1 or waking, REM onset latency 
(ROL; time from sleep onset to beginning of first REM period), 
time spent in each stage of sleep.
Wilson et al. 1087
Blood sampling for analysis of drug 
concentration
Blood samples for vortioxetine and paroxetine analysis were 
drawn at five time points on day 1 (pre-dose, 2, 4, 8 and 12 hours 
post-dose), at one time point on day 2 (time-matched to day 1 
pre-dose), at two time points on day 3 (time-matched to day 1 
pre-dose and 12 hours) and at one time point on day 4 (time-
matched to day 1 pre-dose).
Statistical methods (PSG)
For each of the PSG variables, a mixed model analysis of the 
raw, post-dose values was performed. The model included 
treatment and period as fixed factors. The covariance matrix 
across treatments within subject was unstructured, and the 
Kenward-Roger method for adjustment of the degrees of free-
dom was used. Based on this mixed model analysis, the treat-
ment-specific least squares (LS) means and the pairwise 
treatment contrasts were estimated with 95% confidence limits 
and, for the pairwise comparisons, the associated p-value for 
no difference.
A corresponding set of sensitivity analyses was performed for 
the change from baseline (day -1) for the post-dose values. The 
model included treatment and period as fixed factors and the 
baseline was included as a covariate. The covariance matrix 
within subject was unstructured across treatments, and the 
Kenward-Roger method for adjustment of the degrees of free-
dom was used. Based on this mixed model analysis, the baseline-
adjusted treatment-specific LS mean change from baseline (day 
-1) and the pairwise treatment contrasts were estimated with 95% 
confidence limits and, for the pairwise comparisons, the associ-
ated p-value for no difference (no adjustment for multiple tests). 
Since 5 of the 24 subjects dropped out, an additional set of sensi-
tivity analyses of the raw values was performed to preclude bias 
due to carry-over effects. The same approach as in the original 
analyses was used, except that the systematic effects consisted of 
the three factors: the (current) treatment, the period and the treat-
ment (40mg vortioxetine, 20mg vortioxetine, 20mg paroxetine, 
placebo or none) in the preceding period.
Pharmacokinetic/pharmacodynamic 
modelling
The individual exposure of vortioxetine during the EEG measure-
ments (i.e. the night between day 3 and day 4), denoted Cav,sleep, 
was estimated by non-linear mixed effect analysis using a previ-
ously developed population pharmacokinetic model for meta-
analysis based upon the data obtained in healthy subjects (Areberg 
et al., 2012b). Due to the very sparse sampling schedule, all 
parameters were fixed to the previous model results. The individual 
exposure to paroxetine during the EEG measurements was esti-
mated as the average of the day 3 and pre-dose day 4 values. The 
following PSG variables were used as pharmacodynamic (PD) 
parameters in the pharmacokinetic/pharmacodynamics (PK/PD) 
analysis: wake after sleep onset (WASO), sleep stage 1 (S1), total 
sleep time (TST), REM onset latency (ROL) and total time spent 
in REM sleep (TREM). The influence of a potential periodic 
effect was assessed by applying a mixed model for each PSG 
parameter, with treatment, sequence and period (1–4) as fixed 
effects and subject as a random effect. If period was significant it 
was included as a covariate in the further PK/PD modelling. The 
relationship, if any, between Cav,sleep and the main PSG parameters 
was investigated by non-linear mixed effect analysis using an Emax 
or a simple linear model. The Emax model for baseline corrected 
PSG parameters (Δpar) for subject i used for the PK/PD analysis 
was






i= + + +−0 0, , ,( ) / ( )
γ γ γ ε
where C is the plasma concentration of vortioxetine/paroxetine, 
E0 is the effect at C = 0 (i.e. placebo treatment), Emax the maxi-
mum effect, EC50 the plasma concentration of vortioxetine/par-
oxetine required for half the maximum effect, γ the Hill factor 
and εi the residual error. The relationship was regarded signifi-
cant if the 95% confidence interval for Emax did not include zero. 
The linear model was of the form
∆par  E  k  Ci i i i= + − +0, ε
In addition, uncorrected PSG values (i.e. day 3 only) were analysed 
using the same models and the same parameters. No covariate anal-
ysis was performed. Nonlinear and linear mixed effect modelling 
was performed with the NONMEM® software (ICON Development 
Solutions), version 7. The first-order conditional error with interac-
tion (FOCE INTER) minimisation method was used.
SERT occupancy data
The expected SERT occupancies at the time of the EEG measure-
ments were estimated by translating the Cav,sleep values to SERT 
occupancy using the published PK/PD (occupancy) relationships 
for vortioxetine (Areberg et al., 2012a) and paroxetine (Meyer 
et al., 2004).
Results
Twenty-four subjects were randomised to treatment and 19 sub-
jects completed the study. Five subjects withdrew from the study: 
two were withdrawn because actigraphy measurements showed 
that they were repeatedly non-compliant with regard to sleep-
wake routine; one was withdrawn at the decision of the physician 
(non-compliance with actigraph procedure on two occasions); 
one withdrew consent; one was withdrawn because of taking a 
prohibited concomitant medication (chlorpheniramine).
The Cav,sleep for vortioxetine was 13.8 ng/mL for 20mg and 
29.5 ng/mL for 40mg. The Cav,sleep for paroxetine 20mg was 11.7 
ng/mL.
Sleep architecture
There was a significant reduction in REM sleep and increase in 
ROL after all drugs compared with placebo; REM sleep suppres-
sion after vortioxetine was dose-related, and there was no signifi-
cant difference between vortioxetine 40mg and paroxetine on 
ROL or TREM (see Table 1). Stage 1 sleep was also significantly 
increased after all drugs, and WASO was significantly increased 
after vortioxetine 40mg (Table 1).
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Pharmacokinetic/pharmacokinetic (PK/PD) 
analysis
No significant period effect for the PSG parameters was found. 
The popPK model used for estimations of Cav,sleep for vortioxetine 
was predictive and reliable.
REM onset latency (ROL)
Clear and significant relationships were found for both vortioxe-
tine and paroxetine plasma concentration for ROL using an Emax 
model (Table 2; Figures 1 and 2).
Time spent in REM sleep (TREM)
Clear and significant relationships were found for both vortioxe-
tine and paroxetine using an Emax model (Table 3).
Intra-sleep wakening (WASO)
Emax models did not converge but linear models revealed a weak 
but significant relationship for vortioxetine, both for baseline cor-
rected and uncorrected data. For paroxetine, neither Emax models 
nor linear models gave a significant relationship (Table 4).
Total sleep time (TST)
No significant relationship was observed for vortioxetine or par-
oxetine using either Emax or linear models, regardless of whether 
corrected or uncorrected values were used.
Sleep stage 1 (S1)
Linear models revealed a significant relationship for uncor-
rected data (but not for baseline corrected data) for both 
Table 1. PSG sleep parameters (mean ± SD).
Night Placebo Vortioxetine 20mg Vortioxetine 40mg Paroxetine 20mg
-1 3 -1 3 -1 3 -1 3
Total sleep time 435 413 442 403 430 393* 442 399*
 ±20 ±29 ±15 ±44 ±28 ±51 ±17 ±44
Sleep onset latency 21 38 20 49 29 42 19 44
 ±14 ±25 ±15 ±36 ±20 ±29 ±16 ±30
REM onset latency 61 63 64 127***# 61 231*** 58 261***
 ±11 ±18 ±14 ±45 ±18 ±65 ±15 ±98
Total REM sleep 117 108 115 63***# 113 41*** 118 39***
 ±24 ±21 ±16 ±20 ±19 ±22 ±20 ±22
Wake after sleep onset 28 31 22 31 27 45* 23 37
 ±13 ±18 ±10 ±15 ±16 ±31 ±15 ±26
Stage 1 sleep 40 43 44 51* 45 68*** 44 56**
 ±14 ±16 ±11 ±19 ±14 ±29 ±16 ±22
Stage 2 sleep 133 121 142 146 127 140 134 148
 ±30 ±25 ±35 ±35 ±35 ±42 ±30 ±30
Slow wave sleep 145 141 141 143 146 147 146 155
 ±30 ±23 ±28 ±29 ±25 ±25 ±28 ±29
Significantly different from placebo: *p < 0.05, **p < 0.01, ***p < 0.001.
Significantly different from paroxetine: #p < 0.001.
Table 2. Parameter values for the plasma concentrations versus ΔROL (change from baseline) relationship for vortioxetine and paroxetine.
Parameter Vortioxetine Paroxetine
Population mean (RSEa) Inter-individual 
variability (%)
Population mean (RSEa) Inter-individual variability (%)
Emax (min) 250 (7.4) 29 297 (5.8) 3.1
EC50 (ng/mL) 21 (6.1) – 6.2 (15) 34
E0 (min) 2.4 (135) – -2.8 (132) –
Γ 2.5 (22) 74 2.3 (18) 1.1
ε (SD) (ng/mL) 15 (35) – 15 (35) –
The models were of the form DROL = E + E *C / EC + C  + 0 max av,sleep 50 av,sleep( ) ε .
aRelative standard error (RSE) expressed as percentage of SE/mean; 95% CIs for Emax are 216 to 284 (vortioxetine) and 263 to 331 (paroxetine).
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vortioxetine and paroxetine. Emax modelling did not converge 
(Table 5).
Occupancy
By translating vortioxetine/paroxetine Cav,sleep values to estimated 
SERT occupancy, the effects of vortioxetine and paroxetine on 
ΔROL were clearly separated. Also at a given SERT occupancy, 
vortioxetine affected REM sleep to a lesser degree than paroxe-
tine. Linear regression analysis of SERT occupancy versus ΔROL 
showed that both the intercepts and slopes were statistically sig-
nificantly (p < 0.01) different between vortioxetine and paroxe-
tine (Figure 3). For clarification of this we plotted plasma levels 
of the drugs versus SERT occupancy and plasma levels of the 
drugs versus REM suppression (Figure 4). For paroxetine these 
were very similar but for vortioxetine they were clearly 
different.
Discussion
We found as expected that both antidepressants had significant 
effects on suppression of REM sleep and that these effects were 
closely related to plasma levels, and to the estimated SERT occu-
pancy. The relationship of REM variables to plasma level has 
been shown for fluoxetine (Feige et al., 2002) in humans and to 
plasma levels and SERT occupancy in rodents (Geldof et al., 
2007), but this is the first time that the relationship between REM 
suppression and SERT occupancy has been reported in humans. 
Importantly, this relationship was different for vortioxetine and 
paroxetine.
SSRIs have been shown to suppress REM sleep (decrease total 
REM sleep and increase ROL) in several studies, both in healthy 
subjects and depressed patients. REM sleep suppression after SSRI 
administration is probably caused by increased synaptic 5-HT lev-
els. Assuming a direct relationship between SERT occupancy and 
5-HT level, one would expect to find the two relationships (plasma 
levels of the SSRI versus SERT occupancy and plasma levels of 
the SSRI versus REM suppression) to be very similar. This is what 
was found for paroxetine in this study, but not for vortioxetine. 
This indicates that the two compounds are clearly distinguishable, 
implying that vortioxetine has a different clinical pharmacological 
profile compared with the SSRI paroxetine, which is most proba-
bly related to its interactions with 5-HT receptors.
Since SRIs are thought to suppress REM via stimulation of 
5-HT1A receptors, and vortioxetine is both an SRI and a 5-HT1A 
agonist, it might have been expected that REM suppression 
would be substantially more with vortioxetine than paroxetine. 
However, this was not the case. As far as we are aware there has 
been no previous human study of an SRI plus a 5-HT1A agonist, 
in comparison with SRI alone, on sleep to determine if there is an 
additive effect.
It has been suggested that 5-HT3 receptor agonism might sup-
press REM in rodents (Monti and Jantos, 2008; see also 
Figure 1. Plasma concentrations versus ΔROL (change from baseline) 
for paroxetine.
Figure 2. Plasma concentrations versus ΔROL (change from baseline) 
for vortioxetine.
Table 3. Parameter values for the plasma concentrations versus ΔTREM (change from baseline) relationship for vortioxetine and paroxetine.
Parameter Vortioxetine Paroxetine
Population mean (RSEa) Inter-individual variability (%) Population mean (RSEa) Inter-individual variability (%)
Emax (min) -149 (38) – -119 (22) –
EC50 (ng/mL) 36 (65) 48 7.1 (57) 34
E 0 (min) -9.0 (51) – -8.9 (51) –
Γ – – – –
ε (SD) (ng/mL) 19 (25) – 20 (37) –
The models were of the form DTREM = E + E *C / EC + C  + 0 max av,sleep 50 av,sleep( ) ε.
aRelative standard error (RSE) expressed as percentage of SE/mean; 95% CIs for Emax are -298 to -38 (vortioxetine) and -170 to -68 (paroxetine).
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companion paper Leiser et al., this issue) and humans (Staner 
et al., 2001) and that 5-HT3 receptor antagonism may decrease 
ROL in humans (Rothe et al., 1994). These effects in humans are 
modest but most likely contribute to our results, as the very high 
affinity of vortioxetine for the 5-HT3 receptor means that even at 
low plasma concentrations this receptor is likely to be saturated 
(Bang-Andersen et al., 2011). As SERT occupation increases then 
synaptic 5-HT levels will also increase, offsetting the actions of the 
5-HT3 receptor blockade. The other receptor interactions are less 
likely explanations as both 5-HT1A receptor partial agonism and 
5-HT7 receptor antagonism tend to increase REM latency and 
decrease TREM (Bonaventure et al., 2012; Wilson et al., 2005).
We used the average overnight plasma concentration of the 
drugs as the PK variable in the PK/PD analysis of sleep variables, 
and of course this is not optimal; however, any attempt to do more 
Table 4. Parameter values for ΔWASO PK/PD models.
Parameter Vortioxetine
Population mean (RSEa) Inter-individual variability (%)
k (min/ng/mL) 0.48 (30) 27
E0 (min) 1.6 (233) 215
ε (SD) (ng/mL) 18 (35) –
The models were of the form DWASO = E + k *C + 0 av,sleep ε .
aRelative standard error (RSE) expressed as percentage of SE/mean.
Table 5. Parameter values for S1 PK/PD.
Parameter Vortioxetine Paroxetine
Population mean (RSEa) Inter-individual variability (%) Population mean (RSEa) Inter-individual variability (%)
k (min/ng/mL) 0.72 (29) 85 1.2 (33) 36
E0 (min) 42 (8.5) 30 41 (9.0) 30
ε SD (ng/ml) 10 (21) – 10 (40) –
The models were of the form DS1 = E + k *C + 0 av,sleep ε.
aRelative standard error (RSE) expressed as percentage of SE/mean.
Figure 3. Estimated SERT occupancy versus ΔROL.
Figure 4. (a) Models for predicted ΔROL and SERT occupancy versus 
plasma concentrations (paroxetine). (b) Models for predicted ΔROL and 
SERT occupancy versus plasma concentrations (vortioxetine).
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frequent sampling would have disrupted sleep. In fact, the plasma 
concentrations of the drugs remained fairly stable overnight, with 
an approximately 20–25% drop from evening to morning, and no 
difference between the two drugs. The SERT occupancy estimates 
used here were measured in the striatum for paroxetine, and in the 
raphe for vortioxetine, but the SERT occupancy versus plasma 
exposure relationships were very similar between raphe nuclei 
and striatum (J. Areberg, unpublished results).
Other known effects of SRIs that we found were increased 
stage 1 sleep, increased intra-sleep wake and decreased TST. These 
were seen with all active treatments and there was no significant 
difference between vortioxetine and paroxetine. There was a weak 
positive relationship (using Emax model) between intra-sleep wake 
time and plasma levels of vortioxetine. The fact that these effects 
on sleep maintenance are similar between the two drugs is interest-
ing in the light of the lower incidence of subject-reported sleep 
disturbance in clinical trials with vortioxetine compared with those 
with SSRIs (Sanchez et al., 2015). However, because of the load-
ing dose regime we used it is difficult to draw any useful conclu-
sions from our data regarding clinical implications.
This study is the first to explore the impact of the multimodal 
antidepressant vortioxetine on sleep parameters and in compari-
son with paroxetine, a pure SRI. We found a clear suppression of 
REM sleep with both drugs, consistent with increased synaptic 
5-HT concentration. However, the relationships between the 
SERT occupancies (calculated from PET in human brain for each 
drug) and the extent of REM suppression, showed different pro-
files, with vortioxetine producing a different effect on REM sleep 
from that expected for an SRI which also has 5-HT1A agonist 
properties. The most probable explanation is that the 5-HT3 
receptor antagonism of vortioxetine partly offsets REM suppres-
sion produced by 5-HT reuptake blockade and 5-HT1A agonism, 
because of its very much higher affinity for 5-HT3 receptors than 
5-HT1A (Sanchez et al., 2015). These findings provide evidence 
that vortioxetine has a multimodal action in humans.
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